Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Non Randomized, Open Label, Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase.

NCT01605981 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT01605981
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01605981 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Non Randomized, Open Label, Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase.
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 4
Overall status
Withdrawn
Start date
February 28, 2014
Completion date
January 31, 2017
Enrollment
0 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloid leukemia (cml)